Simultaneous Integrated Boost in Once-weekly Hypofractionated Radiotherapy for Breast Cancer in the Elderly: Preliminary Evidence.
Radiotherapy
breast cancer
elderly
hypofractionation
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
08
07
2019
revised:
23
07
2019
accepted:
30
07
2019
entrez:
31
10
2019
pubmed:
31
10
2019
medline:
20
3
2020
Statut:
ppublish
Résumé
To evaluate once-weekly hypofractionated radiotherapy in elderly patients affected by early breast cancer, reporting acute and late toxicity profiles, and treatment feasibility. Fifty patients were treated with a hypofractionated regimen: 28.5±2.5 Gy in five fractions at one fraction weekly. Simultaneous integrated boost (SIB) to the tumor bed in high-risk cases. patients over 70 years old, pT1-2, N0-1a. Acute and late toxicities were assessed based on Radiation Therapy Oncology Group. The median follow-up was 20 months and the median patient age was 79 years. SIB was added for 22 patients (44%). Grade 3-4 acute cutaneous toxicities were not observed; grade 2 toxicity occurred only in four patients (8%). Late subcutaneous tissue toxicity consisted of grade 2 fibrosis in two patients (4%), grade 1 in five (10%) and grade 0 in 41(85%). Limiting fraction numbers with a safer profile may improve the management of breast cancer for the elderly.
Identifiants
pubmed: 31662528
pii: 33/6/1985
doi: 10.21873/invivo.11694
pmc: PMC6899087
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1985-1992Informations de copyright
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Cancer Radiother. 2018 Oct;22(6-7):635-639
pubmed: 30143463
Lancet. 2011 Nov 12;378(9804):1707-16
pubmed: 22019144
Pract Radiat Oncol. 2018 May - Jun;8(3):145-152
pubmed: 29545124
Int J Radiat Oncol Biol Phys. 2017 Jul 1;98(3):595-602
pubmed: 28581400
Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6
pubmed: 7713792
Radiat Oncol. 2010 Nov 22;5:111
pubmed: 21092219
Rep Pract Oncol Radiother. 2012 Feb 01;17(2):66-70
pubmed: 24377002
Cancer Med. 2013 Oct;2(5):712-7
pubmed: 24403236
Lancet Oncol. 2015 Mar;16(3):266-73
pubmed: 25637340
Acta Oncol. 2013 May;52(4):703-10
pubmed: 23421926
Med Phys. 2008 Sep;35(9):4161-72
pubmed: 18841869
Comput Methods Programs Biomed. 2018 Mar;155:199-208
pubmed: 29512500
Radiother Oncol. 2005 Apr;75(1):6-8
pubmed: 15878094
Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):76-81
pubmed: 19168297
Lancet Oncol. 2008 Apr;9(4):331-41
pubmed: 18356109
Aging Clin Exp Res. 2017 Feb;29(Suppl 1):149-157
pubmed: 27837457
N Engl J Med. 2010 Feb 11;362(6):513-20
pubmed: 20147717
Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):563-570
pubmed: 28126305
Anticancer Res. 2010 Nov;30(11):4749-53
pubmed: 21115935
J Clin Oncol. 2013 Jul 1;31(19):2382-7
pubmed: 23690420
Ann Surg Oncol. 2013 Oct;20(10):3274-8
pubmed: 23838924
Clin Breast Cancer. 2015 Aug;15(4):270-6
pubmed: 25666079
Breast Care (Basel). 2012 Dec;7(6):453-9
pubmed: 24715826
Radiother Oncol. 2011 Jul;100(1):93-100
pubmed: 21752481
Lancet Oncol. 2013 Oct;14(11):1086-1094
pubmed: 24055415
Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):154-62
pubmed: 15629606
Int J Radiat Oncol Biol Phys. 2017 Jul 15;98(4):715-717
pubmed: 28602405
JAMA. 2001 Feb 21;285(7):885-92
pubmed: 11180731
Rep Pract Oncol Radiother. 2012 Jul 15;18(1):26-33
pubmed: 24381744
Radiother Oncol. 2016 Jul;120(1):114-8
pubmed: 27046390
Ann Oncol. 2010 Apr;21(4):748-53
pubmed: 19825884
Anticancer Res. 2013 Aug;33(8):3503-7
pubmed: 23898126